Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Bentham Science Publishers Ltd. full text link Bentham Science Publishers Ltd. Free PMC article
Full text links

Actions

Share

Review
.2008 Sep;9(7):598-610.
doi: 10.2174/138920008785821710.

CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme

Affiliations
Review

CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme

Hongbing Wang et al. Curr Drug Metab.2008 Sep.

Abstract

Human CYP2B6 has been thought to account for a minor portion (<1%) of total hepatic cytochrome P450 (CYP) content and to have a minor function in human drug metabolism. Recent studies, however, indicate that the average relative contribution of CYP2B6 to total hepatic CYP content ranges from 2% to 10%. An increased interest in CYP2B6 research has been stimulated by the identification of an ever-increasing substrate list for this enzyme, polymorphic and ethnic variations in expression levels, and evidence for cross-regulation with CYP3A4, UGT1A1 and several hepatic drug transporters by the nuclear receptors pregnane X receptor and constitutive androstane receptor. Moreover, 20- to 250-fold interindividual variation in CYP2B6 expression has been demonstrated, presumably due to transcriptional regulation and polymorphisms. These individual differences may result in variable systemic exposure to drugs metabolized by CYP2B6, including the antineoplastics cyclophosphamide and ifosfamide, the antiretrovirals nevirapine and efavirenz, the anesthetics propofol and ketamine, the synthetic opioid methadone, and the anti-Parkinsonian selegiline. The potential clinical significance of CYP2B6 further enforces the need for a comprehensive review of this xenobiotic metabolizing enzyme. This communication summarizes recent advances in our understanding of this traditionally neglected enzyme and provides an overall picture of CYP2B6 with respect to expression, localization, substrate-specificity, inhibition, regulation, polymorphisms and clinical significance. Emphasis is given to nuclear receptor mediated transcriptional regulation, genetic polymorphisms, and their clinical significance.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pie charts for hepatic CYP expression and their contribution to metabolism of clinically-used drugs. (A) Relative hepatic expression of CYP content. (B) Contribution to drug metabolism. Due to substrate overlap among CYP isozymes, the total of contributions is moderately >100%.
Fig. 2
Fig. 2
Human CAR preferentially binds DR4 containing CYP2B6-PBREM over ER6 containing CYP3A4-PXRE. ChIP assay was performed in a V5-hCAR stable HepG2 cell line (Yh-18)[160]. (A) PCR amplification efficiency was tested by using in put DNA. (B) DNA extracted from V5-antibody or anti-mouse IgG precipitated chromatin was analyzed by PCR. DEC2 was used as a non hCAR target gene control as described previously [161].
Fig. 3
Fig. 3
Human CAR translocates in CAR -/- mouse liver in response to CLZ. A fluorescent-hCAR (EYFP-hCAR) was introduced into CAR -/- mice through tail vein injection, and mice was then treated with CLZ (90 mg/kg body weight), or DMSO, intraperitoneally. Animals were sacrificed 7 h later, and frozen liver sections were prepared for analysis by confocal microscopy as described previously [99].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. Pharmacogenetics. 1996;6(1):1–42. - PubMed
    1. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. Pharmacogenetics. 2004;14(1):1–18. - PubMed
    1. Nelson DR. Hum Genomics. 2005;2(3):196–201. - PMC - PubMed
    1. Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M, Ingelman-Sundberg M. Drug Metab Dispos. 2001;29(11):1480–4. - PubMed
    1. Purnapatre K, Khattar SK, Saini KS. Cancer Lett. 2008;259(1):1–15. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Bentham Science Publishers Ltd. full text link Bentham Science Publishers Ltd. Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp